Aluminum Hydroxide
drugOn this page
Also known as Alu-capAludroxAluminium hydroxideAluminium hydroxide geldriedAluminum hydroxide component of gavisconDried aluminum hydroxide gelNSC-664400Sarpep
Summary
Aluminum Hydroxide (CHEMBL1200706) is an approved small-molecule antacid (ATC A02AB01); indicated across 22 conditions including nicotine dependence and avian influenza.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A02AB01
- Indications: 22 conditions
- Clinical trials: 20
- Chemistry: 81.028 Da · AlH6O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200706 |
| Name | Aluminum Hydroxide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 6328211 |
| ChEBI | CHEBI:33130 |
| ATC | A02AB01 |
| Molecular formula | AlH6O3 |
| Molecular weight | 81.028 |
| InChIKey | MXRIRQGCELJRSN-UHFFFAOYSA-N |
SMILES: O.O.O.[Al]
Pharmacological roles (ChEBI): antacid, flame retardant.
Also known as: Alu-cap, Aludrox, Aluminium hydroxide, Aluminium hydroxide gel, dried, Aluminum hydroxide, Aluminum hydroxide component of gaviscon, Dried aluminum hydroxide gel, NSC-664400, Sarpep, ALUMINUM HYDROXIDE
Parent form; salt/anhydrous children: CHEMBL3833310, CHEMBL3833390
Patent coverage: 191,174 distinct patent families (495,977 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 495,600 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
22 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| nicotine dependence | 2 | MONDO:0008575 | EFO:0003768 |
| avian influenza | 2 | MONDO:0018695 | EFO:0005222 |
| streptococcal pneumonia | 2 | MONDO:0005972 | EFO:1001474 |
| anthrax infection | 2 | MONDO:0005119 | EFO:0000778 |
| hookworm infectious disease | 2 | MONDO:0005799 | EFO:0007314 |
| stomatitis | 2 | MONDO:0004842 | EFO:0009688 |
| type 1 diabetes mellitus | 2 | MONDO:0005147 | MONDO:0005147 |
| severe acute respiratory syndrome | 1 | MONDO:0005091 | EFO:0000694 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| cutaneous leishmaniasis | 1 | MONDO:0005446 | EFO:0005046 |
| staphylococcus aureus infection | 1 | MONDO:0005545 | EFO:0005681 |
| malaria | 1 | MONDO:0005136 | EFO:0001068 |
| dengue disease | 1 | MONDO:0005502 | EFO:0005547 |
| Plasmodium falciparum malaria | 1 | MONDO:0005920 | EFO:0007444 |
| schistosomiasis | 1 | MONDO:0015254 | EFO:1001475 |
| influenza | 1 | MONDO:0005812 | EFO:0007328 |
| plague | 1 | MONDO:0019095 | EFO:0009425 |
| respiratory syncytial virus infectious disease | 1 | MONDO:0001577 | EFO:1001413 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 20.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 12 |
| PHASE1/PHASE2 | 4 |
| Not specified | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01336530 | PHASE3 | TERMINATED | Tepilta® Versus Oxetacaine, Antacids and Placebo |
| NCT00263744 | PHASE1/PHASE2 | COMPLETED | Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive |
| NCT00280033 | PHASE1/PHASE2 | COMPLETED | H5 Adult - Chiron Study of Bird Flu Vaccine |
| NCT00294099 | PHASE1/PHASE2 | COMPLETED | H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults |
| NCT00296634 | PHASE1/PHASE2 | COMPLETED | H5 Vaccine Alone or With Adjuvant in Healthy Adults |
| NCT00529399 | PHASE2 | COMPLETED | Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects |
| NCT00000779 | PHASE1 | COMPLETED | A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3 |
| NCT00000809 | PHASE1 | WITHDRAWN | Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women |
| NCT00000868 | PHASE1 | COMPLETED | A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers |
| NCT00001042 | PHASE1 | COMPLETED | A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals |
| NCT00001044 | PHASE1 | COMPLETED | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults. |
| NCT00001052 | PHASE1 | COMPLETED | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults |
| NCT00001053 | PHASE1 | COMPLETED | A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects |
| NCT00002402 | PHASE1 | COMPLETED | A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines |
| NCT00382980 | PHASE1 | COMPLETED | Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults |
| NCT00533741 | PHASE1 | WITHDRAWN | SARS Coronavirus Vaccine (SARS-CoV) |
| NCT00974935 | PHASE1 | COMPLETED | Phase I STEBVax in Healthy Adults |
| NCT04368585 | PHASE1 | COMPLETED | Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects |
| NCT00018135 | Not specified | COMPLETED | Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals |
| NCT00031109 | Not specified | COMPLETED | The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.